Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
6.69
-0.03 (-0.45%)
At close: Feb 21, 2025, 4:00 PM
6.80
+0.11 (1.64%)
After-hours: Feb 21, 2025, 4:33 PM EST
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aldeyra Therapeutics stock have an average target of 10, which predicts an increase of 49.48% from the current stock price of 6.69.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 9, 2024.
Analyst Ratings
The average analyst rating for Aldeyra Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +49.48% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +49.48% | Aug 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +49.48% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $10 | Buy | Reiterates | $10 | +49.48% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $10 | Hold → Buy | Upgrades | $10 | +49.48% | Apr 3, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
85.44M
EPS This Year
-0.94
from -0.64
EPS Next Year
-0.47
from -0.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 209.1M | 77.1M | |||
| Avg | n/a | 85.4M | 57.3M | |||
| Low | n/a | 6.9M | 37.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | -9.7% | |||
| Avg | - | - | -32.9% | |||
| Low | - | - | -55.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.89 | 1.71 | 0.20 | |||
| Avg | -0.94 | -0.47 | -0.21 | |||
| Low | -0.98 | -1.01 | -0.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.